Qualiber, Inc.

We are transforming existing FDA approved therapeutics and making them more effective and less toxic, improving outcomes for cancer patients

  • Stage Product In Development
  • Industry Biotechnology
  • Location Chapel Hill, NC, USA
  • Currency USD
  • Founded April 2010
  • Employees 3
  • Website qualiberinc.com

Company Summary

Qualiber has developed a novel drug delivery nanotechnology (nanoCLIPD) that has the potential to transform existing (previously FDA approved) therapeutics across multiple disease areas. We are developing more effective and less toxic therapeutics for cancer using this drug delivery platform consequently providing greater clinical benefit and longer survival to patients.

Team

  • Anil K Goyal, Ph.D.
    President and CEO

    • >20 years at venture-backed and public biotechnology companies.
    • Led business development, marketing, licensing, mergers/acquisitions and technology development for drugs and diagnostics.
    • Co-founded Qualiber, Inc. in 2010.
    • Head of BizDev @ Ascletis, Inc., a Hangzhou, China specialty/pharma.
    • Management experience includes roles at Optherion, Serenex, Millennium Pharmaceuticals, Genome Therapeutics Corporation and Merck & Co.

  • Leaf Huang, Ph.D.
    Co-Founder and CSO

    • 30+ years of drug delivery R&D experience with liposome drugs & gene-delivery
    • Recipient of The Alec D. Bangham Achievement Award in liposome research
    • Founder of 4 other companies: PDS Biotech, Lipella, Lipogen, Rgene Therapeutics

  • Anil Goyal, Ph.D., CLP™

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free